Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes

Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldwide and one of the main causes of death in diabetic patients. It is also acknowledged as an independent risk factor for cardiovascular disease (CVD). Since sitagliptin was approved, many studies have...

Full description

Bibliographic Details
Main Author: Mega, Cristina (author)
Other Authors: Lemos, Edite Teixeira de (author), Fernandes, Rosa (author), Reis, Flávio (author)
Format: article
Language:eng
Published: 2017
Subjects:
Research in Type 2 diabetes mellitus (T2DM)
Renoprotection
DPP-4 inhibitors
Sitagliptin
ZDF rat
Diabetic nephropathy therapeutic
Online Access:http://hdl.handle.net/10400.19/4704
Country:Portugal
Oai:oai:repositorio.ipv.pt:10400.19/4704

Internet

http://hdl.handle.net/10400.19/4704

Similar Items